• Recruiting

NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM

MagnetisMM-8

NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory Multiple Myeloma

ELRANATAMAB

MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory Multiple Myeloma


Study C1071008 includes 2 parts. The objective of Phase 1b part is to establish the safety profile in order to confirm the monotherapy RP2D in Chinese participants. The Phase 2 part is a single stage design to evaluate the efficacy and safety in Chinese participants. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.


Sponsor

Pfizer


Location

China

 

ClinicalTrials.gov Identifier: NCT05228470


Official Title: A PHASE 1B/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF ELRANATAMAB (PF-06863135) IN CHINESE PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY


First Posted : February 8, 2022


Click here for details on Clinicaltrials.gov

 

Elranatamab


Elranatamab (Code C146860)

Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135

B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135

BCMA x CD3 Bispecific Antibody PF-06863135

BCMA-CD3 Bispecific Ab PF-06863135

Elranatamab

ELRANATAMAB

PF 06863135

PF-06863135

PF06863135

RN 613

RN-613

RN613

 

Locations

China

China, Fujian

China, Guangdong

China, Heilongjiang

China, Jiangsu

China, Shandong





Posts Archive